Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156782 | 1.00 | EPHX1 (0.43) | EPHX1SLC6A2SLC6A4SLC6A3CPN1 | |
| SCHEMBL27832973 | 0.91 | CPN1 (0.45) | EPHX1CPN1CPB2ALPIPKM | |
| SCHEMBL23751456 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| SCHEMBL22764999 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| SCHEMBL22765000 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| SCHEMBL23751460 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| SCHEMBL22765044 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| SCHEMBL23751454 | 0.88 | CPN1 (0.48) | CPN1CPB2ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL22750398 | 0.87 | CPN1 (0.47) | CPN1CPB2ALPIPKMPTGS1 | |
| Hydrochloric Acid SCHEMBL22750413 | 0.87 | CPN1 (0.47) | CPN1CPB2ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | EPHX1 1357/4885SLC6A2 2162/4885SLC6A4 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.